Search

Your search keyword '"Annagrazia Cecere"' showing total 3 results
Start Over Author "Annagrazia Cecere" Journal journal of the american college of cardiology
3 results on '"Annagrazia Cecere"'

1. TCT-808 Comparison between Clopidogrel and the New Oral P2Y12 Inhibitors in the Treatment of Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention

Author

Emanuela De Cillis, Stefano Favale, Martino Pepe, Annagrazia Cecere, O. Burattini, Alessandro Santo Bortone, Alessandro Cafaro, Luca Amato, Nicola Forzati, and Francesco Giardinelli

Subjects
medicine.medical_specialty, Prasugrel, business.industry, medicine.medical_treatment, Percutaneous coronary intervention, Clopidogrel, P2Y12, Internal medicine, medicine, Cardiology, In patient, cardiovascular diseases, Cardiology and Cardiovascular Medicine, business, Ticagrelor, circulatory and respiratory physiology, medicine.drug
Abstract

Dual antiplatelet therapy improves angiographic results of primary percutaneous coronary intervention (pPCI) in patients with STEMI. The new oral P2Y12 inhibitors (P2Y12-I) prasugrel and ticagrelor are the gold-standard drugs because of a faster and more intense effect when compared to clopidogrel.

Published
2018

2. IMPACT OF ADMISSION PLASMA GLUCOSE LEVEL ON MYOCARDIAL PERFUSION IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) PATIENTS

Author

Nicola Signore, Martino Pepe, Stefano Favale, Alessandro Santo Bortone, Annagrazia Cecere, Filippo Masi, D Quagliara, Antonio Tito, and D. Zanna

Subjects
medicine.medical_specialty, business.industry, Elevation, Electrocardiography in myocardial infarction, medicine.disease, Plasma glucose level, Internal medicine, medicine, Cardiology, ST segment, Myocardial infarction, Cardiology and Cardiovascular Medicine, business, Perfusion
Published
2017

3. TIME RELATED BENEFIT OF ANTIPLATELET THERAPY ON CORONARY REPERFUSION IN ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) PATIENTS

Author

D. Zanna, D Quagliara, Nicola Signore, Stefano Favale, Alessandro Santo Bortone, Filippo Masi, Antonio Tito, Martino Pepe, and Annagrazia Cecere

Subjects
medicine.medical_specialty, Prasugrel, business.industry, medicine.medical_treatment, Percutaneous coronary intervention, Coronary reperfusion, Clinical prognosis, P2Y12, St elevation myocardial infarction, Internal medicine, medicine, Cardiology, Onset of action, Cardiology and Cardiovascular Medicine, business, Ticagrelor, medicine.drug
Abstract

Background: The goal of STEMI treatment is early reperfusion. The new oral P2Y12 inhibitors (P2Y12-I) prasugrel and ticagrelor demonstrated to improve angiographic results of primary percutaneous coronary intervention (pPCI) and clinical prognosis, but their onset of action is significantly impaired

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results